USPTO Examiner WITHERSPOON SIKARL A - Art Unit 1692

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18968658PROCESS FOR REDUCING BY-PRODUCTS IN BISPHENOL A REACTION SYSTEMDecember 2024May 2025Allow600NoNo
18924505BISPHENOL A PREPARATION PROCESS AND DEVICE THEREOFOctober 2024April 2025Allow500NoNo
18856957SYNTHESIS AND PURIFICATION OF CBDAOctober 2024February 2025Allow400NoNo
18794655PROCESS FOR DEBROMINATION OF NOVEL BROMINATED FLAME RETARDANTS USING Zn-BASED ADDITIVESAugust 2024December 2024Allow400NoNo
18654660LIPID FORMULATIONS FOR GENE EDITINGMay 2024January 2025Allow910NoNo
18614086SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPYMarch 2024January 2025Allow1010NoNo
18602836Methods Of Treating Multiple SclerosisMarch 2024March 2025Allow1210NoNo
18416953METHODS OF TREATMENT WITH COMBINATIONS OF CANNABIDIOL AND PSILOCYBINJanuary 2024April 2025Allow1520NoNo
18416577RXR AGONIST SALT FORM, POLYMORPHS THEREOF, AND USES THEREOFJanuary 2024February 2025Allow1310NoNo
18510437OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND USES THEREOFNovember 2023February 2025Allow1510NoNo
18388698HYDROXY GAS GENERATORNovember 2023March 2025Allow1610NoNo
18489642COMBINATION THERAPY USING RILUZOLE TO ENHANCE TUMOR SENSITIVITY TO IONIZING RADIATIONOctober 2023February 2025Allow1610NoNo
18488342PRODRUGS OF TREPROSTINILOctober 2023March 2025Allow1720NoNo
18381035METHODS FOR REMOVING PESTICDES FROM CANNABIS PRODUCTSOctober 2023March 2025Abandon1710NoNo
18479002METHOD FOR PREPARING PICKERING MINIEMULSION AND ITS CATALYTIC APPLICATIONSeptember 2023September 2024Allow1100NoNo
18458741METHOD AND SYSTEM FOR EXTRACTION OF MINERALS BASED ON DIVALENT CATIONS FROM BRINEAugust 2023January 2025Allow1710NoNo
18239013SYSTEMS, APPARATUS AND METHODS FOR SEPARATING ACTINIUM, RADIUM, AND THORIUMAugust 2023May 2025Allow2020NoNo
18352623PROCESS FOR PURIFICATION OF PRODUCTSJuly 2023February 2025Allow1910NoNo
18349693SOLID PEROXYALPHAHYDROXYCARBOXYLIC ACID GENERATION COMPOSITIONS AND THE USE THEREOFJuly 2023November 2024Allow1610NoNo
18213947TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAMEJune 2023March 2025Allow2010NoNo
18335877PSYCHOTROPIC AGENTS AND USES THEREOFJune 2023February 2025Abandon2010NoNo
18334815METHOD FOR MAKING ALDEHYDES, ALCOHOLS, AMIDES, AND CARBOXYLIC ACIDS FROM PLASTIC PYROLYSIS OILJune 2023February 2025Allow2020NoNo
18198899DIRECT CATALYTIC CONVERSION OF ALCOHOLS TO OLEFINS OF HIGHER CARBON NUMBER WITH REDUCED ETHYLENE PRODUCTIONMay 2023November 2024Allow1820NoNo
18198809Branched Aldehyde ProductionMay 2023February 2025Allow2120NoNo
18316471HETEROCYCLIC COMPOUNDS, PREPARATION METHODS THEREFOR, AND METHODS OF USES THEREOFMay 2023August 2024Allow1500NoNo
18133846SYSTEM AND METHOD FOR TREATMENT OF PLANTS FOR SYNTHESIS OF COMPOUNDS THEREFROMApril 2023August 2024Allow1610NoNo
18177450PROCESS OF PREPARING 3-FLUORO-5(((1R,2AR)-3,3,4,4-TETRAFLUORO-1,2A-DIHYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)-OXY)BENZONITRILEMarch 2023February 2025Allow2410NoNo
18111822Synthetic Cannabinoid Compounds for Treatment of Pain and AnxietyFebruary 2023June 2024Allow1600NoNo
18170858THERAPEUTIC COMPOUNDS AND COMPOSITIONSFebruary 2023July 2024Allow1700NoNo
18164309PROCESS FOR PREPARING TAPINAROFFebruary 2023December 2024Allow2210NoNo
18164136BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTSFebruary 2023January 2025Allow2310NoNo
18102761CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDEJanuary 2023September 2024Allow2010NoNo
18094663Systems for Removal of Detergents from Aqueous SolutionsJanuary 2023September 2024Allow2010NoNo
18079984METHODS FOR ISOLATING COMPOUNDSDecember 2022December 2024Allow2420NoNo
18076902FLUID CATALYTIC CRACKING OF P-CRESOL DIMER INTO PHENOLIC MONOMERS AND PROCESS THEREOFDecember 2022January 2025Allow2500NoNo
17999978Organic Catalyst for Non-Aqueous Aldol CondensationNovember 2022April 2025Allow2910NoNo
17990777Topical Medicament for Use in Treatment of Anorectal InflammationNovember 2022December 2024Allow2420NoNo
17990991POST EXTRACTION PURIFICATION OF TERPENESNovember 2022January 2025Allow2600NoNo
18057394METHOD FOR CONTINUOUS SYNTHESIS OF ACYLNAPHTHALENE WITH ACYLATION LIQUIDNovember 2022March 2025Allow3800NoNo
17999273METHODS OF ARENE ALKENYLATIONNovember 2022April 2025Allow2910NoNo
17923284POLYMORPHIC FORMS OF (R)-OXYBUTYNIN HYDROCHLORIDENovember 2022July 2025Allow3220NoNo
17965145COMPOUNDS AND USES THEREOFOctober 2022September 2024Allow2310NoNo
17963549METHOD FOR PRODUCING (METH)ACRYLOXY GROUP-CONTAINING ORGANOSILICON COMPOUNDSOctober 2022June 2025Allow3201NoNo
17960092ORGANIC ANION LITHIUM IONIC COCRYSTAL COMPOUNDS AND COMPOSITIONSOctober 2022December 2024Allow2710NoNo
17954874ALKOXYLATED SECONDARY ALCOHOLSeptember 2022September 2024Allow2310NoNo
17951560Treatment of Parasitic Infections of Fish SurfacesSeptember 2022May 2025Allow3200NoNo
17906843Hydroformylation Catalysts Comprising Fluorophosphine Ligands and Precursors ThereofSeptember 2022April 2025Allow3110NoNo
17946905COMPOSITIONS AND METHODS FOR TREATMENT OF PRE-CANCEROUS SKIN LESIONSSeptember 2022August 2024Allow2310NoNo
17821967PRODUCTION OF GLYCOLALDEHYDE BY THERMOLYTIC FRAGMENTATIONAugust 2022October 2024Allow2610NoNo
17800452Use of a Multidentate Phosphite Ligand in the Catalytic Synthesis of AdiponitrileAugust 2022April 2025Allow3200NoNo
17904208CALPAIN-2 INHIBITOR COMPOUNDS AND METHODS OF TREATMENTAugust 2022April 2025Allow3200NoNo
17798607LOW-PRESSURE HYDROFORMYLATION OF DIISOBUTENEAugust 2022December 2024Allow2800NoNo
17795723METHOD AND SYSTEM FOR OXIDIZING CUMENE AND HYDROCARBONSJuly 2022March 2025Allow3210NoNo
17759436A METHOD FOR DIRECT HYDROGENATION OF MALEIC ANHYDRIDE TO PRODUCE 1,4-BUTANEDIOL AND CO-PRODUCE SUCCINIC ANHYDRIDEJuly 2022April 2025Allow3300NoNo
17865037CURCUMINOIDS, ANALOGS THEREOF, AND METHODS OF MAKING THE SAMEJuly 2022January 2025Allow3020NoNo
17808877CANNABIS PROCESSING SYSTEMS AND METHODSJune 2022December 2024Allow3010NoNo
17847215PROCESS OF MAKING PSEUDOIONONE AND HYDROXY PSEUDOIONONE IN AQUEOUS MIXTURES COMPRISING CITRAL AND ACETONE, COMPRISING ADDING FIRST AND SECOND AMOUNTS OF HYDROXIDEJune 2022November 2024Abandon2910NoNo
17788237DEHYDROGENATION PROCESSJune 2022November 2024Allow2900NoNo
17785586PROCESS FOR THE PREPARATION OF BRIVARACETAMJune 2022April 2025Allow3400NoNo
17784015PREPARATION METHOD FOR OPTICALLY ACTIVE CITRONELLALJune 2022November 2024Allow2900NoNo
17834382DIMETHYLCYCLOBUTANONE COMPOUNDS, DIMETHYLCYCLOBUTANE COMPOUNDS, AND PROCESSES FOR PREPARING THE SAMEJune 2022August 2024Allow2610NoNo
17834151PROCESS FOR THE PRODUCTION OF 1,4-BUTANEDIOL FROM RENEWABLE SOURCES AND POLYESTERS OBTAINED THEREFROMJune 2022August 2024Allow2710NoNo
17775856METHODS TO SEPARATE CANNABINOIDS FROM IMPURITIES BY CRYSTALLIZATIONMay 2022April 2025Allow3500NoNo
17739507THERMOLYTIC FRAGMENTATION OF SUGARS USING RESISTANCE HEATINGMay 2022October 2024Allow2910NoNo
17773961PROCESS FOR CONVERTING METHANOL TO FORMALDEHYDEMay 2022September 2024Allow2910NoNo
17773287INDIUM PRECURSOR COMPOUND, METHOD OF PREPARING THIN FILM USING THE SAME, AND BOARD PREPARED USING THE SAMEApril 2022December 2024Allow3211NoNo
17771721FLUORINE SUBSTITUTED CYCLOHEXENE ANALOGUES OF GAMMA- AMINOBUTYRIC ACID (GABA)April 2022June 2025Allow3810NoNo
17726860METHODS OF MODIFYING A NATURALLY OCCURRING CANNABIS RAW PLANT MATERIAL, A PURIFIED CANNABIS PRODUCT FROM A NATURALLY OCCURRING CANNABIS RAW PLANT MATERIAL, AND A MODIFIED CANNABIS PRODUCT FROM A NATURALLY OCCURRING CANNABIS RAW PLANT MATERIALApril 2022April 2025Allow3510NoNo
17725853SPIRO-BISPHOSPHOROUS COMPOUND, AND PREPARATION AND APPLICATION THEREOFApril 2022September 2024Allow2900NoNo
17769151METHOD FOR PRODUCING 2,4-DIALKYLBENZALDEHYDEApril 2022August 2024Allow2810NoNo
17769200CONTINUOUS POST-TREATMENT METHOD AND DEVICE FOR PENEM COMPOUNDApril 2022March 2025Allow3500NoNo
17764450ASTAXANTHIN ESTERS AND METHODS OF USE THEREOFMarch 2022February 2025Allow3500NoNo
17763718LIGHT INDUCED CATALYTIC C-H OXYGENATION OF ALKANESMarch 2022November 2024Allow3210NoNo
177005033,3,3',3'-TETRAMETHYL-1,1'-SPIROBIINDANE-7,7'-DIOLMarch 2022January 2025Allow3410NoNo
17684020COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENTMarch 2022November 2024Allow3310NoNo
17680560CONTINUOUS HYDROLYZATION APPARATUS AND CONTINUOUS HYDROLYZATION METHODFebruary 2022January 2025Allow3510NoNo
176357112,2,6-TRIMETHYL-4,5-DIHYDRO-3H-OXEPINE AS AROMA INGREDIENTFebruary 2022February 2025Allow3600NoNo
17592449SUPERCRITICAL FLUID EXTRACTION PROCESS WITH INTEGRATED PRESSURE EXCHANGERFebruary 2022July 2024Allow3000NoNo
17631583SEPARATION OF CANNABINOIDS FROM MIXTURES THEREOF BY EXTRACTION AND DISTILLATIONJanuary 2022July 2025Abandon4110NoNo
17597822RECYCLE CONTENT (C4)ALKANALJanuary 2022May 2025Allow4020NoNo
17630130ISOLATION OF CHROMOPLASTID CAROTENOIDS FROM FRUITSJanuary 2022August 2024Allow3000NoNo
17627153METHOD FOR THE TREATMENT OF A COMPOSITION COMPRISING NATURAL VANILLINJanuary 2022September 2024Allow3210NoNo
17622377WNT ACTIVATORS AND METHODS OF USEDecember 2021May 2025Abandon4110NoNo
17559745METHOD AND APPARATUS FOR MANUFACTURING NITROGEN TETROXIDEDecember 2021August 2024Allow3210NoNo
17645189MULTIPLE CHARGED IONIC COMPOUNDS DERIVED FROM POLYAMINES AND COMPOSITIONS THEREOF AND METHODS OF PREPARATION THEREOFDecember 2021September 2024Allow3310NoNo
17556804CATALYST FOR DEHYDROGENATION OF LIGHT ALKANESDecember 2021June 2024Allow3010NoNo
17619329COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERSDecember 2021July 2024Allow3110NoNo
176440451,4-DISUBSTITUTED PYRIDAZINE ANALOGS THERE OF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED CONDITIONSDecember 2021April 2025Abandon4010NoNo
17548249PROCESS FOR REMOVING THC FROM CANNABINOIDSDecember 2021May 2024Allow2911NoNo
17541235Branched ProductsDecember 2021August 2023Allow2120NoNo
17610487METHODS AND MATERIALS FOR TREATING CANCERNovember 2021May 2025Abandon4210NoNo
17519266DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITISNovember 2021March 2025Allow4010NoNo
17606711METHOD FOR PREPARING ACRYLONITRILE DIMEROctober 2021March 2025Allow4110NoNo
17602909METHOD OF TREATING TUMOURSOctober 2021October 2024Allow3600NoNo
17593662FUNGICIDAL COMPOUNDSSeptember 2021July 2024Allow3410NoNo
17440415D-METYROSINE COMPOSITIONS AND METHODS FOR PREPARING SAMESeptember 2021October 2024Abandon3710NoNo
17311020METHOD FOR PRODUCING 3,5-DIHYDROXY-4-METHOXYBENZYL ALCOHOL FROM BIVALVEJune 2021November 2024Allow4230YesNo
17298692PROCESS FOR PRODUCING 1-(4-ISOBUTYLPHENYL)ETHANOL BY HYDROGENATION OF 1-(4-ISOBUTYL-PHENYL)ETHANONE IN THE PRESENCE OF A CATALYST COMPOSITION COMPRISING COPPERJune 2021March 2025Allow4630NoNo
17290355ORGANOSULFUR COMPOUNDSApril 2021May 2024Abandon3710NoNo
16845032CROTONYL ALCOHOL CASSIC ACID ESTER WITH ANTIBACTERIAL ACTIVITY AND A METHOD OF PREPARING THE SAMEApril 2020May 2020Allow200NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WITHERSPOON, SIKARL A.

Strategic Value of Filing an Appeal

Total Appeal Filings
6
Allowed After Appeal Filing
4
(66.7%)
Not Allowed After Appeal Filing
2
(33.3%)
Filing Benefit Percentile
90.7%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 66.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner WITHERSPOON, SIKARL A - Prosecution Strategy Guide

Executive Summary

Examiner WITHERSPOON, SIKARL A works in Art Unit 1692 and has examined 361 patent applications in our dataset. With an allowance rate of 97.5%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 18 months.

Allowance Patterns

Examiner WITHERSPOON, SIKARL A's allowance rate of 97.5% places them in the 92% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WITHERSPOON, SIKARL A receive 0.84 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WITHERSPOON, SIKARL A is 18 months. This places the examiner in the 93% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +2.5% benefit to allowance rate for applications examined by WITHERSPOON, SIKARL A. This interview benefit is in the 21% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 41.5% of applications are subsequently allowed. This success rate is in the 92% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 69.2% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 43.3% are granted (fully or in part). This grant rate is in the 46% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 17.2% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.6% of allowed cases (in the 51% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.